tumor drug delivery
Recently Published Documents


TOTAL DOCUMENTS

75
(FIVE YEARS 23)

H-INDEX

18
(FIVE YEARS 4)

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Jun-Yong Wu ◽  
Yong-Jiang Li ◽  
Jiemin Wang ◽  
Xiong-Bin Hu ◽  
Si Huang ◽  
...  

AbstractTargeted drug delivery to the glioblastoma (GBM) overcoming blood–brain barrier (BBB) has been challenging. Exosomes are promising vehicles for brain tumor drug delivery, but the production and purification hinder its application for nanomedicine. Besides, the formation of protein corona (PC) may affect the behaviour of nanocarriers. Here, multifunctional exosomes-mimetics (EM) are developed and decorated with angiopep-2 (Ang) for enhancing GBM drug delivery by manipulating PC. Docetaxel (DTX)-loaded EM with Ang modification (DTX@Ang-EM) show less absorption of serum proteins and phagocytosis by macrophages. Ang-EM show enhanced BBB penetration ability and targeting ability to the GBM. Ang-EM-mediated delivery increase the concentration of DTX in the tumor area. The multifunctional DTX@Ang-EM exhibits significant inhibition effects on orthotopic GBM growth with reduced side effects of the chemotherapeutic. Findings from this study indicate that the developed DTX@Ang-EM provide a new strategy for targeted brain drug delivery and GBM therapy. Graphical abstract


2021 ◽  
Author(s):  
Julian S Rechberger ◽  
Charlotte A Brown ◽  
Frederic Thiele ◽  
Erica A Power ◽  
David J Daniels

Graphical abstract [Formula: see text]


2021 ◽  
Vol 6 (10) ◽  
pp. 3473-3484
Author(s):  
Xin Li ◽  
Helin Li ◽  
Changchang Zhang ◽  
Andrij Pich ◽  
Lingxi Xing ◽  
...  

Pharmaceutics ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 1193
Author(s):  
David J. Lundy ◽  
Helen Nguyễn ◽  
Patrick C. H. Hsieh

Treatment of brain tumors is challenging since the blood–brain tumor barrier prevents chemotherapy drugs from reaching the tumor site in sufficient concentrations. Nanomedicines have great potential for therapy of brain disorders but are still uncommon in clinical use despite decades of research and development. Here, we provide an update on nano-carrier strategies for improving brain drug delivery for treatment of brain tumors, focusing on liposomes, extracellular vesicles and biomimetic strategies as the most clinically feasible strategies. Finally, we describe the obstacles in translation of these technologies including pre-clinical models, analytical methods and regulatory issues.


2021 ◽  
Vol 22 (3) ◽  
Author(s):  
Susheel Kumar Nethi ◽  
Shubhmita Bhatnagar ◽  
Swayam Prabha

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Li-Juan Ma ◽  
Ruichao Niu ◽  
Xi Wu ◽  
Jun Wu ◽  
En Zhou ◽  
...  

AbstractClinical translation of poly (lactic-co-glycolic acid) (PLGA)-based nanomedicine is limited, partly because of the poor delivery efficiency resulting from non-specific phagocytosis by phagocytes. Understanding the nanoparticle interplay between cancer cells and immune cells remains largely elusive. In this study, a quantitative investigation on cellular internalization of fluorescent PLGA particles (100 nm, 500 nm, and 1 µm) against laryngeal carcinoma cells with or without monocytes/macrophages in monoculture or co-culture systems was first performed. PLGA particles at concentrations of 5–20 µg/mL show superior biocompatibility except for 500 nm and 1 µm PLGA particles at 20 µg/mL slightly reduce cell viability. Microscopic observation has discovered all three sizes of particles are effectively ingested by both cancer cells and macrophages; however, quantitative fluorescence examination has disclosed that the uptake index of cancer cells (mean intracellular particle fluorescence per cancer cell normalized to that of per macrophage) is substantially declined for all PLGA particles in co-cultures compared to that in monocultures (1.35–1.05, 1.50–0.59, and 1.4–0.47 for 100 nm, 500 nm, and 1 µm particles, respectively). Quantitative analysis using flow cytometry further confirmed the reduced uptake index of cancer cells in co-cultures, but higher particle counts per macrophage. It has also been found that the formation of multinucleated giant cells via the fusion of macrophages increased after PLGA treatment, which could be further exploited as a potential approach for tumor drug delivery. Overall, these findings provide new insights into the interaction of nanoparticle-immune-cancer cells, which may facilitate the application of PLGA-based nanocarriers for the treatment of laryngeal carcinoma.


Author(s):  
Jessica I. Griffith ◽  
Jann N. Sarkaria ◽  
William F. Elmquist

2021 ◽  
Vol 11 (2) ◽  
pp. 88
Author(s):  
Nithya Subrahmanyam ◽  
Hamidreza Ghandehari

The extracellular matrix (ECM) plays an active role in cell life through a tightly controlled reciprocal relationship maintained by several fibrous proteins, enzymes, receptors, and other components. It is also highly involved in cancer progression. Because of its role in cancer etiology, the ECM holds opportunities for cancer therapy on several fronts. There are targets in the tumor-associated ECM at the level of signaling molecules, enzyme expression, protein structure, receptor interactions, and others. In particular, the ECM is implicated in invasiveness of tumors through its signaling interactions with cells. By capitalizing on the biology of the tumor microenvironment and the opportunities it presents for intervention, the ECM has been investigated as a therapeutic target, to facilitate drug delivery, and as a prognostic or diagnostic marker for tumor progression and therapeutic intervention. This review summarizes the tumor ECM biology as it relates to drug delivery with emphasis on design parameters targeting the ECM.


2020 ◽  
Vol 327 ◽  
pp. 70-87
Author(s):  
Francis Combes ◽  
Evelyne Meyer ◽  
Niek N. Sanders

Sign in / Sign up

Export Citation Format

Share Document